CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BTP53MutationPrognosticSupportsPoor OutcomeHead And Neck Squamous Cell CarcinomaAlsner et al., 2001
BTP53Truncating MutationPrognosticSupportsPoor OutcomeHead And Neck Squamous Cell CarcinomaLindenbergh-van der Plas et al., 2011
BTP53Truncating MutationPrognosticDoes Not SupportPoor OutcomeHead And Neck Squamous Cell CarcinomaLindenbergh-van der Plas et al., 2011
BKRASG12/G13PredictiveSupportsResistancePancreatic AdenocarcinomaTrametinib,GemcitabineInfante et al., 2014
DCDK12Loss-of-functionPredictiveSupportsSensitivity/ResponseOvarian Serous CarcinomaOlaparibBajrami et al., 2014
BIDH2R172DiagnosticSupportsPositivePeripheral T-cell LymphomaCairns et al., 2012
BIKZF1DeletionPrognosticSupportsPoor OutcomeB-lymphoblastic Leukemia/lymphomaBeldjord et al., 2014
DNT5C2R367QPredictiveSupportsResistanceT-cell Acute Lymphoblastic LeukemiaThioguanine,MercaptopurineTzoneva et al., 2013
DNT5C2K359QPredictiveSupportsResistanceT-cell Acute Lymphoblastic LeukemiaMercaptopurine,ThioguanineTzoneva et al., 2013
DNT5C2D407APredictiveSupportsResistanceT-cell Acute Lymphoblastic LeukemiaMercaptopurine,ThioguanineTzoneva et al., 2013
DNT5C2R367QPredictiveDoes Not SupportResistanceT-cell Acute Lymphoblastic LeukemiaNelarabine,ArabinosylguanineTzoneva et al., 2013
DNT5C2D407APredictiveDoes Not SupportResistanceT-cell Acute Lymphoblastic LeukemiaArabinosylguanine,NelarabineTzoneva et al., 2013
DNT5C2K359QPredictiveDoes Not SupportResistanceT-cell Acute Lymphoblastic LeukemiaArabinosylguanine,NelarabineTzoneva et al., 2013
BTP53MutationPrognosticSupportsPoor OutcomeB-lymphoblastic Leukemia/lymphomaHof et al., 2011
BTP53DNA Binding Domain MutationPrognosticSupportsPoor OutcomeOral Squamous Cell CarcinomaYamazaki et al., 2003
BPTENLossPredictiveSupportsResistanceBladder CarcinomaEverolimusSeront et al., 2013
BEGFRT790MPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaRociletinibSequist et al., 2015
BBRCA2Loss-of-functionPredictiveSupportsSensitivity/ResponseProstate CancerOlaparibMateo et al., 2015
AKITExon 11 MutationPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorImatinibHeinrich et al., 2003
BXRCC1R194WPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaDocetaxel,Vinorelbine,GemcitabineSun et al., 2009
DGSTP1DeletionPredictiveSupportsSensitivity/ResponseOvarian CarcinomaCarboplatin,Paclitaxel,CisplatinSawers et al., 2014
DBIRC7AmplificationPredictiveSupportsResistanceColon CancerCisplatinDing et al., 2013
DEGFRExon 4 DeletionPredictiveSupportsResistanceEpithelial Ovarian CancerCisplatinZhang et al., 2013
BNT5C2K359QPrognosticSupportsPoor OutcomeAcute Lymphoblastic LeukemiaTzoneva et al., 2013
BEZH2Intron 6 MutationPrognosticSupportsPoor OutcomeColorectal CancerCrea et al., 2012
BGSTP1I105VPredictiveSupportsSensitivity/ResponseColorectal CancerFOLFOX RegimenChen et al., 2010
BXRCC1Q399RPrognosticSupportsBetter OutcomeLung Non-small Cell CarcinomaLiao et al., 2012
BXRCC1Q399RPredictiveSupportsSensitivity/ResponseCervical CancerCisplatin,CarboplatinChung et al., 2006
BERCC2K751QPredictiveSupportsResistanceOsteosarcomaCisplatinCaronia et al., 2009
DFGFR1ExpressionPredictiveSupportsSensitivity/ResponseLung CancerPonatinibWynes et al., 2014
BFGFR1AmplificationPrognosticSupportsPoor OutcomeLung Squamous Cell CarcinomaKim et al., 2013
BFGFR1AmplificationPrognosticSupportsPoor OutcomeCancerChang et al., 2014
DFGFR1AmplificationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaPD173074Dutt et al., 2011
BFGFR1AmplificationPrognosticDoes Not SupportPoor OutcomeLung Squamous Cell CarcinomaJiang et al., 2015
Av::ROS1FusionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaCrizotinibShaw et al., 2014
BATRI774FSPrognosticSupportsPoor OutcomeEndometrial CancerZighelboim et al., 2009
BEGFRAmplificationPredictiveDoes Not SupportSensitivity/ResponseHead And Neck Squamous Cell CarcinomaCetuximab,Platinum Compound,FluorouracilLicitra et al., 2011
BEGFROverexpressionPredictiveDoes Not SupportSensitivity/ResponseHead And Neck Squamous Cell CarcinomaCetuximabLicitra et al., 2013
BEGFROverexpressionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorPirker et al., 2012
BCDKN2Ap16 ExpressionPrognosticSupportsBetter OutcomeHead And Neck Squamous Cell CarcinomaArgiris et al., 2014
BCDKN2Ap16 ExpressionPredictiveDoes Not SupportResistanceHead And Neck Squamous Cell CarcinomaCetuximabPogorzelski et al., 2014
BCD274ExpressionPrognosticDoes Not SupportPoor OutcomeLung Non-small Cell CarcinomaZhong et al., 2015
BCD274ExpressionPredictiveSupportsSensitivity/ResponseMelanomaPembrolizumab,NivolumabCarbognin et al., 2015
DPTENLossPredictiveSupportsResistanceBreast CancerAlpelisibJuric et al., 2015
CEGFRS492RPredictiveSupportsResistanceColorectal CancerCetuximabMontagut et al., 2012
CBRAFL597RPredictiveSupportsSensitivity/ResponseMelanomaVemurafenibBahadoran et al., 2013
BERBB3OverexpressionPredictiveSupportsResistanceColorectal CancerCetuximabCushman et al., 2015
BEZH2OverexpressionPrognosticSupportsPoor OutcomeCancerJiang et al., 2016
DMETAmplificationPredictiveSupportsResistanceLung Non-small Cell CarcinomaGefitinibEngelman et al., 2007
BPDGFRAD842VPredictiveSupportsResistanceGastrointestinal Stromal TumorImatinibYoo et al., 2016
Page 8 of 96
PreviousNext